LY-2599666
- Generic Name
- LY-2599666
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Phase 1
Terminated
- Conditions
- HealthyAlzheimer's DiseaseMild Cognitive Impairment
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT02614131
- Locations
- 🇺🇸
Parexel Early Phase Unit at Glendale, Glendale, California, United States
🇺🇸CRI Lifetree, Marlton, New Jersey, United States
🇺🇸PRA Health Sciences, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath